海泰新光（688677）：公司内窥镜业务和光学业务持续高增长

Investment Rating - The investment rating for the company is "Buy" [8] Core Views - The company has shown strong growth in its endoscope and optical businesses, with a revenue increase of 40.47% year-on-year for the first three quarters of 2025, reaching 448 million yuan, and a net profit increase of 40.03%, amounting to 136 million yuan [4][5] - The endoscope business grew by 40% in the first three quarters of 2025, with a significant increase of over 100% in the third quarter compared to the same period in 2024 [5] - The optical business also experienced over 30% growth, driven by collaborations with domestic and international diagnostic equipment companies and the expansion into other optical applications [5] Financial Performance - For 2025, the company is projected to achieve revenues of 602 million yuan, 724 million yuan in 2026, and 869 million yuan in 2027, with year-on-year growth rates of 35.89%, 20.30%, and 20.11% respectively [6] - The net profit attributable to the parent company is expected to be 184 million yuan in 2025, 227 million yuan in 2026, and 281 million yuan in 2027, with growth rates of 36.22%, 22.97%, and 23.78% respectively [6] - The company's price-to-earnings (P/E) ratio is projected to decrease from 29.45 in 2025 to 19.35 in 2027, indicating improving valuation metrics [6]